{
  "slug": "johnson-johnson",
  "symbol": "JNJ",
  "name": "Johnson & Johnson",
  "fiscalYearEnd": "2025-12-28",
  "filing": {
    "accession": "0000200406-26-000016",
    "form": "10-K",
    "filed": "2026-02-11",
    "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm"
  },
  "model": "claude-haiku-5-5",
  "promptVersion": "2026-10-31.2",
  "generatedAt": "2026-10-31T20:54:57.760612+00:00",
  "segments": {
    "currency": "USD",
    "asOf": "2025-12-28",
    "total": 94193000000.0,
    "internal": null,
    "rows": [
      {
        "name": "Innovative Medicine",
        "revenue": 60401000000.0,
        "share": 64.1
      },
      {
        "name": "MedTech",
        "revenue": 33792000000.0,
        "share": 35.9
      }
    ]
  },
  "sections": {
    "businessModel": [
      {
        "de": "Das Unternehmen hat zwei Geschäftssegmente: Innovative Medicine und MedTech.",
        "en": "The company has two business segments: Innovative Medicine and MedTech.",
        "quote": "The Company is organized into two business segments: Innovative Medicine and MedTech."
      },
      {
        "de": "Das Vision-Portfolio umfasst ACUVUE-Kontaktlinsen und TECNIS-Intraokularlinsen für Katarakt-Operationen sowie weitere Produkte für Katarakt- und refraktive Eingriffe.",
        "en": "The Vision portfolio includes ACUVUE contact lenses and TECNIS intraocular lenses for cataract surgery, plus other products for cataract and refractive procedures.",
        "quote": "The Vision portfolio includes contact lenses marketed under the ACUVUE brand, TECNIS premium intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures."
      },
      {
        "de": "Das Segment Innovative Medicine konzentriert sich auf Therapiegebiete wie Onkologie, mit Beispielen wie Prostatakrebs, Blutkrebs, Lungenkrebs und Blasenkrebs.",
        "en": "The Innovative Medicine segment focuses on therapeutic areas such as oncology, with examples including prostate cancer, blood cancers, lung cancer and bladder cancer.",
        "quote": "The Innovative Medicine segment is focused on the following therapeutic areas: Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer)"
      },
      {
        "de": "Zu den wichtigsten Produkten des Segments Innovative Medicine gehört CARVYKTI, eine CAR-T-Zelltherapie für Patienten mit rezidiviertem oder refraktärem multiplem Myelom.",
        "en": "Key products in the Innovative Medicine segment include CARVYKTI, a CAR-T-cell therapy for patients with relapsed or refractory multiple myeloma.",
        "quote": "Key products in the Innovative Medicine segment include: CARVYKTI (ciltacabtagene autoleucel), a chimeric antigen receptor (CAR)-T-cell therapy for the treatment of patients with relapsed/refractory multiple myeloma;"
      }
    ],
    "customers": [
      {
        "de": "Der Umsatz mit Produkten von Innovative Medicine und MedTech wird deutlich durch Erstattungen von Drittzahlern beeinflusst, etwa staatliche Gesundheitsprogramme, private Krankenversicherungen und Managed-Care-Organisationen.",
        "en": "Sales of Innovative Medicine and MedTech products are significantly affected by reimbursements from third-party payors, such as government healthcare programs, private insurance plans and managed care organizations.",
        "quote": "Sales of the Company’s Innovative Medicine and MedTech products are significantly affected by reimbursements by third-party payors such as government healthcare programs, private insurance plans and managed care organizations."
      },
      {
        "de": "MedTech-Produkte werden an Großhändler, Krankenhäuser und Einzelhändler vertrieben und überwiegend von Ärzten, Pflegekräften, Krankenhäusern, Augenfachleuten und Kliniken genutzt.",
        "en": "MedTech products are distributed to wholesalers, hospitals and retailers, and are mainly used by physicians, nurses, hospitals, eye care professionals and clinics.",
        "quote": "These MedTech products are distributed to wholesalers, hospitals, and retailers and are used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics."
      }
    ],
    "competition": [
      {
        "de": "Die Geschäftsbereiche des Unternehmens konkurrieren mit Unternehmen jeder Größe über Kosteneffizienz, technologische Innovationen, geistige Eigentumsrechte, Produktleistung, reale oder wahrgenommene Produktvorteile, Preise, Verfügbarkeit und Erstattungssätze.",
        "en": "The company's businesses compete with companies of all sizes on cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing, availability and reimbursement rates.",
        "quote": "The Company’s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement."
      },
      {
        "de": "Der Wettbewerb in der Forschung, aus internen und externen Quellen, bei der Entwicklung und Verbesserung neuer und bestehender Produkte und Verfahren ist besonders wichtig.",
        "en": "Competition in research, from both internal and external sources, around developing and improving new and existing products and processes is particularly important.",
        "quote": "Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant."
      },
      {
        "de": "Die Tochtergesellschaften des Unternehmens konkurrieren in allen ihren Produktlinien mit Unternehmen lokal und global.",
        "en": "The company's subsidiaries compete with companies both locally and globally in all of their product lines.",
        "quote": "In all of their product lines, the Company’s subsidiaries compete with companies both locally and globally."
      }
    ],
    "risks": [
      {
        "de": "Bei Innovative Medicine folgt auf den Verlust der Patentexklusivität eines Produkts oft ein erheblicher Umsatzrückgang, weil Wettbewerber Zulassungen für Generika, Biosimilars und andere Konkurrenzprodukte erhalten.",
        "en": "For Innovative Medicine, losing patent exclusivity for a product is often followed by a substantial drop in sales, as competitors gain approval for generic, biosimilar and other competing products.",
        "quote": "For the Company’s Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market."
      },
      {
        "de": "Das Unternehmen erwartet, dass Biosimilars von STELARA weltweit weiter auf den Markt kommen, was die STELARA-Umsätze des Unternehmens weiterhin negativ beeinflussen wird.",
        "en": "The company expects biosimilar versions of STELARA to keep launching worldwide, which will continue to negatively affect its sales of STELARA.",
        "quote": "The Company expects continued launches of biosimilar versions of STELARA globally which will continue to negatively impact the Company’s sales of STELARA."
      },
      {
        "de": "Das größte Produkt des Unternehmens, DARZALEX und DARZALEX FASPRO zusammen, machte etwa 15,0 % der Gesamtumsätze im Geschäftsjahr 2025 aus.",
        "en": "The company's largest product, DARZALEX together with DARZALEX FASPRO, accounted for approximately 15.0% of total revenues in fiscal 2025.",
        "quote": "Sales of the Company’s largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 15.0% of the Company's total revenues for fiscal 2025."
      },
      {
        "de": "Das Unternehmen ist Beklagter in zahlreichen Klagen wegen der Verwendung von talkhaltigen Körperpudern, vor allem JOHNSON’S Baby Powder.",
        "en": "The company is a defendant in numerous lawsuits arising from the use of body powders containing talc, mainly JOHNSON’S Baby Powder.",
        "quote": "For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON’S Baby Powder."
      },
      {
        "de": "Das Unternehmen war zunehmenden Patentanfechtungen durch Dritte ausgesetzt, die Generika und Biosimilars seiner wichtigsten Arzneimittel vor dem Ablauf der Patente auf den Markt bringen wollen.",
        "en": "The company has faced increasing patent challenges from third parties seeking generic and biosimilar versions of its key pharmaceutical products prior to patent expiry.",
        "quote": "The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company’s key pharmaceutical products prior to expiration of the applicable patents covering those products."
      }
    ]
  }
}